Evaluating APGE as a current market purchase requires understanding that its share price is tethered closely to the pending all-cash buyout terms offered by AbbVie. Because the acquisition price is fixed, traditional buy-and-hold growth investing strategies no longer apply in the conventional sense, leaving the stock primarily as a low-volatility vehicle for merger-arbitrage participants tracking deal completion timelines.